ARA-290 (Cibinetide)

ARA-290 (Cibinetide)

Nerve Repair • Small-Fiber Neuropathy Support • Anti-Inflammatory Tissue Protection

Benefits of ARA-290

 Neuropathic Pain Support

• Reduced burning and tingling

• Reduced hypersensitivity

• Improved nerve comfort

 Small-Fiber Nerve Regeneration Signalling

• Improved nerve fibre density (human trials)

• Improved nerve health biomarkers

 Anti-Inflammatory Protection

• Reduces inflammatory nerve irritation

• Protects tissues during chronic inflammation

 Improved Functional Outcomes

• Better symptom control

• Improved quality of life metrics in studies

How ARA-290 Works (Mechanisms of Action)

 1. Activates the Innate Repair Receptor (IRR)

ARA-290 selectively activates the innate repair receptor, a protective signalling complex derived from erythropoietin biology that promotes tissue repair without stimulating red blood cell production.

This receptor is responsible for:

• Cellular protection during inflammation

• Tissue repair signalling

• Immune modulation

 2. Supports Small-Fiber Nerve Repair

ARA-290 has been studied in human clinical trials for small-fiber neuropathy, with outcomes including:

• Improved corneal nerve fibre density

• Reduced neuropathic pain symptoms

• Improved nerve function biomarkers

Corneal nerve fibre density is a validated surrogate for small-fiber nerve health.

 3. Modulates Inflammatory Cytokines

ARA-290 reduces harmful inflammation by regulating cytokine activity involved in chronic pain and nerve irritation, including:

• TNF-α

• IL-6

• Other pro-inflammatory mediators

This allows inflammation to settle without suppressing the immune system.

 4. Provides Tissue-Protective Signalling

ARA-290 enhances cell survival pathways in stressed tissues, protecting nerves and surrounding structures from inflammatory and metabolic damage.

 5. Avoids Erythropoiesis & Hormonal Disruption

Unlike erythropoietin (EPO), ARA-290:

• Does not increase red blood cell count

• Does not alter blood viscosity

• Does not affect haemoglobin levels

This significantly improves its safety profile.

What Is ARA-290 (Cibinetide)?

ARA-290 (also known as Cibinetide) is a synthetic peptide designed to activate the body’s innate repair receptor (IRR) — a protective signalling complex that triggers tissue repair, immune modulation, and anti-inflammatory responses without increasing red blood cell production like erythropoietin.

It is among the few peptides with human clinical trial evidence, particularly in treating small-fiber neuropathy in diseases such as sarcoidosis — with objective improvements in nerve fibre metrics and patient-reported neuropathic symptoms.

Dosage, Injection Volume & Cycling

 Concentration:

40 mg / 10 ml (4 mg/ml)

 Dose:

Standard Research-Based Framework:
Daily subcutaneous injection for
28–42 days (based on human trial designs).

Common Dose Ranges (clinic-directed):

• 8 mg daily → 2 ml SC

• 12 mg daily → 3 ml SC

• 16 mg daily → 4 ml SC

Synergy Stacks

 Neuropathy Repair Stack

• ARA-290 + NAD+
  Cellular energy + nerve repair signalling

 Inflammation Control Stack

• ARA-290 + KPV + Glutathione
  Reduces inflammatory drivers + oxidative stress

 Functional Recovery Stack

• ARA-290 + Exercise Physiology
  Improves circulation, nerve tolerance, and functional outcomes

All treatments include a brief consultation and are supervised by qualified clinicians.

Who Is ARA-290 Ideal For?

 Peripheral Neuropathy

• Burning pain

• Tingling

• Electric or hypersensitive nerve pain

 Inflammatory or Autoimmune-Related Neuropathy

• Sarcoidosis-associated neuropathy

• Autoimmune nerve irritation

• Post-viral neuropathic symptoms

 Post-Injury or Post-Inflammatory Nerve Issues

• Nerve damage after inflammation

• Persistent nerve sensitivity

 Clients Seeking Non-Sedating, Non-Opioid Options

• No cognitive impairment

• No addiction potential

 Cycle:

• 4–6 weeks

• Reassess symptoms post-cycle

• Maintenance or repeat cycles as clinically indicated

 Injection Sites:

• Subcutaneous (abdomen or thigh)

 Safety & Side Effects

ARA-290 is well tolerated in clinical trials.

Possible mild effects:

• Mild injection-site redness

• Transient fatigue

• Mild headache

• Temporary nausea (uncommon)

No erythropoiesis, no hormonal disruption, no sedation.

 ARA-290 — Scientific Research & Clinical Studies

(Human clinical evidence available)

Safety and efficacy of cibinetide (ARA-290) in sarcoidosis patients with small-fiber neuropathy
Molecular Medicine
https://link.springer.com/article/10.2119/molmed.2012.00332

Cibinetide improves corneal nerve fibre abundance in sarcoidosis-associated small-fiber neuropathy
IOVS / Europe PMC
https://europepmc.org/article/med/28475703
https://iovs.arvojournals.org/article.aspx?articleid=2625918

Review of erythropoietin-derived tissue protective peptides (ARA-290)
PubMed
https://pubmed.ncbi.nlm.nih.gov/24555851/

ClinicalTrials.gov – ARA-290 in small-fiber neuropathy
https://www.clinicaltrials.gov/study/NCT02039687

EU Clinical Trials Register – Cibinetide results
https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003016-45/results

 Clinical Disclaimer

This page summarises peer-reviewed clinical research and human trial data. ARA-290 at The NAD Clinic is administered under research-based wellness protocols and is not intended to diagnose, treat, or cure disease.

The Miracle Molecule